A universal influenza a vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge

Molecular Therapy

Volumn 18, Issue 12, 2010, Pages 2182-2188

  Zhou, Dongming ^a   Wu, Te Lang ^a,b   Lasaro, Marcio O ^a   Latimer, Brian P ^a   Parzych, Elizabeth M ^a   Bian, Ang ^a   Li, Yan ^a   Li, Hua ^a   Erikson, Jan ^a   Xiang, Zhiquan ^a   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; INFLUENZA VACCINE; PROTEIN M2; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; INFECTION PREVENTION; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N2; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS STRAIN;

ADENOVIRIDAE; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; PAN;

EID: 78650920835     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.202     Document Type: Article

References (33)

1. Thompson, WW, Comanor, L and Shay, DK (2006). Epidemiology of seasonal infuenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194 Suppl 2: S82-S91.
2. Nichol, KL, Mendelman, PM, Mallon, KP, Jackson, LA, Gorse, GJ, Belshe, RB et al. (1999). Effectiveness of live, attenuated intranasal infuenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282: 137-144.
3. Fan, J, Liang, X, Horton, MS, Perry, HC, Citron, M P, Heidecker, GJ et al. (2004). Preclinical study of infuenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
4. Neirynck, S, Deroo, T, Saelens, X, Vanlandschoot, P, Jou, WM and Fiers, W (1999). A universal infuenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
5. Carragher, DM, Kaminski, DA, Moquin, A, Hartson, L and Randall, TD (2008). A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to infuenza virus. J Immunol 181: 4168-4176.
6. Epstein, SL, Kong, W P, Misplon, JA, Lo, CY, Tumpey, TM, Xu, L et al. (2005). Protection against multiple infuenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
7. Yewdell, JW, Bennink, JR, Smith, GL and Moss, B (1985). Infuenza A virus nucleoprotein is a major target antigen for cross-reactive anti-infuenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 1785-1789.
8. McMichael, AJ, Michie, CA, Gotch, FM, Smith, GL and Moss, B (1986). Recognition of infuenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67 (Pt 4): 719-726.
9. Epstein, SL (2006). Prior H1N1 infuenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
10. Mozdzanowska, K, Feng, J, Eid, M, Kragol, G, Cudic, M, Otvos, L Jr et al. (2003). Induction of infuenza type A virus-specifc resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
11. Huleatt, JW, Nakaar, V, Desai, P, Huang, Y, Hewitt, D, Jacobs, A et al. (2008). Potent immunogenicity and effcacy of a universal infuenza vaccine candidate comprising a recombinant fusion protein linking infuenza M2e to the TLR5 ligand fagellin. Vaccine 26: 201-214.
12. Zhao, G, Lin, Y, Du, L, Guan, J, Sun, S, Sui, H et al. (2010). An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 infuenza viruses. Virol J 7: 9.
13. Schotsaert, M, De Filette, M, Fiers, W and Saelens, X (2009). Universal M2 ectodomain-based infuenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
14. Jefferson, TO, Rivetti, D, Di Pietrantonj, C, Rivetti, A, Demicheli, V (2007). Vaccines for preventing infuenza in healthy adults. Cochrane Database Syst Rev 18: CD001269.
15. Smith, S, Demicheli, V, Di Pietrantonj, C, Harnden, AR, Jefferson, T, Matheson, NJ et al. (2006). Vaccines for preventing infuenza in healthy children. Cochrane Database Syst Rev: CD004879.
16. Tatsis, N and Ertl, HC (2004). Adenoviruses as vaccine vectors. Mol Ther 10: 616-629.
17. Zhang, M, Zharikova, D, Mozdzanowska, K, Otvos, L and Gerhard, W (2006). Fine specifcity and sequence of antibodies directed against the ectodomain of matrix protein 2 of infuenza A virus. Mol Immunol 43: 2195-2206.
18. + T cell functionality and mucosal homing. Virology 367: 156-167.
19. Taylor, RM (1941). Experimental infection with infuenza A virus in mice: the increase in intrapulmonary virus after inoculation and the infuence of various factors thereon. J Exp Med 73: 43-55.
20. Nichol, KL, Margolis, KL, Wouremna, J and von Sternberg, T (1996). Effectiveness of infuenza vaccine in the elderly. Gerontology 42: 274-279.
21. Ulmer, JB, Fu, TM, Deck, RR, Friedman, A, Guan, L, DeWitt, C et al. (1998). Protective CD4+ and CD8+ T cells against infuenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648-5653.
22. Lawson, CM, Bennink, JR, Restifo, N P, Yewdell, JW and Murphy, BR (1994). Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing infuenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 68: 3505-3511.
23. Heinen, PP, Rijsewijk, FA, de Boer-Luijtze, EA and Bianchi, AT (2002). Vaccination of pigs with a DNA construct expressing an infuenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with infuenza A virus. J Gen Virol 83(Pt 8): 1851-1859.
24. Lamb, RA, Zebedee, SL and Richardson, CD (1985). Infuenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40: 627-633.
25. Feng, J, Zhang, M, Mozdzanowska, K, Zharikova, D, Hoff, H, Wunner, W et al. (2006). Infuenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3: 102.
26. Liu, W, Zou, P, Ding, J, Lu, Y and Chen, YH (2005). Sequence comparison between the extracellular domain of M2 protein human and avian infuenza A virus provides new information for bivalent infuenza vaccine design. Microbes Infect 7: 171-177.
27. Zharikova, D, Mozdzanowska, K, Feng, J, Zhang, M and Gerhard, W (2005). Infuenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79: 6644-6654.
28. + T cells: implications for their use as vaccines. Blood 110: 1916-1923.
29. Xiang, Z, Li, Y, Cun, A, Yang, W, Ellenberg, S, Switzer, WM et al. (2006). Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerging Infect Dis 12: 1596-1599.
30. Xiang, ZQ, Gao, GP, Reyes-Sandoval, A, Li, Y, Wilson, JM and Ertl, HC (2003). Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77: 10780-10789.
31. Lyons, A, Longfeld, J, Kuschner, R, Straight, T, Binn, L, Seriwatana, J et al. (2008). A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 26: 2890-2898.
32. + T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol 184: 5475-5484.
33. Fitzgerald, JC, Gao, GP, Reyes-Sandoval, A, Pavlakis, GN, Xiang, ZQ, Wlazlo, AP et al. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170: 1416-1422.